Health & Bio2 min read
Health & Bio
FDA Approves New Weekly-Injection Drug for Rare Blood Cancer
The FDA has approved rusfertide, sold as Mimrylo, to treat polycythemia vera, a chronic blood cancer that raises the risk of heart attack, stroke and blood clots.
The U.S. Food and Drug Administration on Friday approved a new treatment for , a rare and slow-growing blood cancer that causes the body to overproduce red blood cells.
The drug, called rusfertide, was developed by the biotech company Protagonist Therapeutics. It will be sold by the Japanese pharmaceutical company Takeda under the brand name Mimrylo, and is administered as a weekly injection.
Polycythemia vera is a chronic blood cancer in which overproduction of red blood cells thickens a patient's blood, raising the risk of life-threatening heart attacks, strokes and blood clots.
Terms explained
The story so far
- FDA Clears First Alzheimer's Blood Test for Patients as Young as 40
- FDA Approves Rasonque, First Drug to Target a Genetic Cause of Pancreatic Cancer
- FDA Clears First Nonmedication PTSD Treatment Using Personalized Brain Stimulation
- FDA Approves New Weekly-Injection Drug for Rare Blood Cancer
#FDA#Mimrylo#rusfertide#Protagonist Therapeutics#Takeda#polycythemia vera
Rate this story